CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ultivue announces the addition of two independent board members, Fenel Eloi and Mary Pat Lancelotta, to help strengthen its position as a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation.

Fenel Eloi is a highly seasoned life sciences executive experienced in leading the transformation of small and mid-size companies to large operating global organizations. Mr. Eloi served as the CFO and then COO at Cell Signaling Technology, a bio-reagents company, from 2005 to 2018, where he provided leadership in the transformation of the company to a global operation. He currently serves on the Board of Directors and chairs the audit committee of 908 Devices, Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis. He also serves on the board of directors of MitoTherapeutix, a privately held drug development biotech company.

“I am very excited to join Ultivue and help them scale their operations to the next level. This is an exciting time for spatial biology and Ultivue has a great opportunity to rapidly grow and favorably impact both their customers’ search for improved cancer treatments and patients’ lives,” said Mr. Eloi.

Mary Pat Lancelotta is currently Vice President, Corporate Marketing and Communications at Adaptive Biotechnologies (Nasdaq: ADPT), a pioneer and leader in immune medicine. She is a seasoned healthcare strategist with a passion for precision medicine and brings over 20 years of business and strategy experience. Prior to Adaptive, Mary Pat led corporate and Product Marketing for Foundation Medicine, a molecular information company. Before joining Foundation Medicine, she led corporate strategic initiatives and strategic planning at Quest Diagnostics. Mary Pat holds an MBA with honors from Columbia Business School and a BS in Biochemistry from Boston College. She is also on the board of directors of Molecular Match, a clinical decision support company, and the TargetCancer Foundation.

“I am delighted to join the Board of Ultivue and look forward to working with the management team and fellow Board members to help grow the business, especially in the area of artificial intelligence to support image analysis,” said Mary Pat Lancelotta. “As we look to the future, working with big pharma, CRO and academic medical center customers, Ultivue has a tremendous opportunity to expand the impact of spatial biology on patients’ lives.”

“It’s an exciting time at Ultivue,” noted Jacques Corriveau, President and CEO. “The combination of Mary Pat’s ability to drive innovative commercial strategy for a global market alongside Fenel’s experience enabling technology advancements within our partnership ecosystem will help our customers bring exciting new therapies to market and positively impact the drive toward personalized cancer treatment.”

About Ultivue

Ultivue, Inc. provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex^® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. For more information, visit ultivue.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210819005101/en/